Mr Michael Nelson United States

Allovate Therapeutics is a specialty pharmaceutical company dedicated to simplifying allergy treatment. Allovate’s approach to allergy immunotherapy is built around the Allerdent® therapeutic platform. 

Allerdent® is formulated as an easy-to-use, customizable toothpaste that incorporates and stabilizes the immunotherapeutic agents used to treat food and respiratory allergies. It conveniently integrates immunotherapy into an allergy sufferer’s everyday brushing routine. Allerdent® makes tackling allergies as simple as brushing your teeth. 

Clinical investigations led by Allovate Therapeutics are developing this platform for the treatment of food allergies. Allerdent® offers the potential of a long-term solution for the 15 million Americans who have food allergies. 

Allergy immunotherapy is the only disease-modifying allergy treatment, demonstrated to be effective in over 100 years of clinical use. This approach changes how the body responds to allergens over time by exposing the immune system to purified allergen extracts in a controlled way over a period of time. Our approach, oral mucosal immunotherapy (OMIT), is designed to overcome the challenges of existing approaches to immunotherapy. OMIT delivers immunotherapeutic agents to the areas of the oral cavity with the greatest potential for reducing allergy symptoms and a lower likelihood of side effects.

Allovate
CFO 

Dr Maria New United States

The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, which includes seven hospital campuses, and has more than 5,000 faculty and nearly 2,000 students, residents and fellows. Our unwavering pursuit of intellectual exchange, breakthrough research, and multidisciplinary teamwork propels us ever forward in biomedical discoveries and advances. We pursue ideas that often challenge conventional wisdom to revolutionize the practice of medicine and produce dramatically better outcomes for patients. We make big, bold bets by investing in radical free thinkers and technology at the cutting edge.

Icahn School of Medicine at Mount Sinai
Pediatric Endocrinologist 

Mr Pascal Nigen United States

ABOUT US: 

Alpha Bronze is a leading provider of investor relations and strategic corporate communications. We have been working with US and non-US private and public companies to build their profiles within the investment community.

Based in New York, Alpha Bronze's single core competency is:

  • the development and execution of tailored, strategic investor communication programs.

Our approach is straightforward: by thoroughly and by leveraging our expertise and knowledge of the "Street", we help our clients:

  • develop clear and consistent key messages,
  • raise their awareness and profiles in the global investment community and,
  • ulimately maximize the market value of their stock and company.
Alpha Bronze
Managing Partner 

Didier Nimal France

OsseoMatrix OsseoMatrix design, manufacture and sell patient specific synthetic bone implants. Industry sectors Medtech Therapeutics Area Dental and Oral Health
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Your innovative solution

OsseoMatrix has developed a direct 3D printing process of biological ceramics which enables the manufacturing of patient specific synthetic bone implants

Which problem are you solving ?

The bioceramic implants developed by OsseoMatrix fit the anatomical complexity of cranio-maxillo-facial or orthopaedic bone losses, resulting of trauma, infection, tumor.

Target market segments

Market 1: Cranio-facial Market 2: Dental Market 3 Orthopaedic 4 Laboratories

Key value proposition

advantage 1 less invasive / advantage 2 same composition as bone / advantage 3 patient specific / advantage 4 regenerative

OSSEOMATRIX
Founding CEO & Chairman 

Dr Raphael Nir United States

SBH Sciences
President